Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Achillion Pharmaceut (ACHN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 409,486
  • Shares Outstanding, K 138,340
  • Annual Sales, $ 0 K
  • Annual Income, $ -85,240 K
  • 36-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.67 +11.61%
on 06/22/18
3.40 -12.48%
on 07/13/18
+0.11 (+3.83%)
since 06/19/18
3-Month
2.67 +11.61%
on 06/22/18
3.93 -24.17%
on 05/21/18
-0.65 (-17.91%)
since 04/19/18
52-Week
2.58 +15.50%
on 02/01/18
5.66 -47.35%
on 08/09/17
-1.38 (-31.65%)
since 07/19/17

Most Recent Stories

More News
Achillion's 3rd Factor D Inhibitor Enters Clinical Studies

Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.

AST : 1.75 (-1.13%)
GHDX : 58.31 (+4.91%)
ACHN : 2.98 (+0.68%)
ALXN : 135.09 (-0.41%)
Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D

- Additional clinical compounds expand factor D portfolio opportunities -

ACHN : 2.98 (+0.68%)
Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

Stock Research Monitor: ACHN, ATNM, and APRI

ACHN : 2.98 (+0.68%)
AMRN : 2.77 (-3.15%)
ATNM : 0.76 (unch)
RAD vs. WBA Which is a Better Stock Ahead of Earnings?

Both Rite Aid and Walgreens Boots Alliance are scheduled to report earnings results on Jun 27 and Jun 28, respectively.

RAD : 1.81 (+2.84%)
ACHN : 2.98 (+0.68%)
WBA : 64.93 (-1.86%)
NKE : 76.95 (+0.47%)
GE : 13.73 (-0.15%)
Achillion to Present at the 2018 JMP Securities Life Sciences Conference

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present at the 2018 JMP Securities Life Sciences Conference on...

ACHN : 2.98 (+0.68%)
Achillion (ACHN) Down 6% Since Earnings Report: Can It Rebound?

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACHN : 2.98 (+0.68%)
Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SK Telecom Co., Ltd. (NYSE:SKM),...

FCAU : 19.53 (+0.51%)
SKM : 23.24 (-0.30%)
PZN : 9.20 (+1.55%)
ACHN : 2.98 (+0.68%)
ADAP : 10.98 (-1.08%)
SSL : 37.18 (-0.69%)
Achillion Pharmaceuticals (ACHN): Moving Average Crossover Alert

Achillion Pharmaceuticals, Inc. (ACHN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

ACHN : 2.98 (+0.68%)
Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43 Annual Health...

ACHN : 2.98 (+0.68%)
DB : 12.02 (-0.50%)
Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO

Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.

PTGX : 7.92 (+1.28%)
LGND : 232.54 (+2.56%)
ACHN : 2.98 (+0.68%)
ALXN : 135.09 (-0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ACHN with:

Business Summary

ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused...

See More

Key Turning Points

2nd Resistance Point 3.08
1st Resistance Point 3.03
Last Price 2.98
1st Support Level 2.91
2nd Support Level 2.84

See More

52-Week High 5.66
Fibonacci 61.8% 4.48
Fibonacci 50% 4.12
Fibonacci 38.2% 3.76
Last Price 2.98
52-Week Low 2.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar